Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
link
Tags
fda
biotech
boehringer ingelheim
cannabis
clinical trials
eli lilly
empagliflozin
europe
europe blog main
europe top stories
government
indiana blog main
indiana top stories
life sciences
marijuana
medical marijuana
national blog main
new york blog main
new york top stories
slgt2 inhibitor
tc
type 1 diabetes
type 2 diabetes
What
approval
3
×
drug
3
×
patients
3
×
cannabis
cbd
epilepsy
fda
treatment
accessibility
announced
approved
based
bid
boehringer
called
chemical
compound
contains
currently
dea
derived
diabetes
driving
eli
epidiolex
epileptic
estimated
expand
fallen
fast
gets
greenlight
huge
impact
ingelheim
lilly
marijuana
marketed
medication
medicine
Language
unset
Current search:
approval
×
patients
×
drug
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@techcrunch.com
5 years ago
With CBD, marijuana-based medicine gets its first greenlight from the FDA
@WIRED
6 years ago
Currently, CBD is a Schedule 1 drug like cannabis, and the DEA must reschedule it before the epilepsy medication can be sold. If approved, this would have ...